Determinants of Complete Pathological Response to Chemoradiation for Rectal Cancer
Pollett W, McLaughlin S, Jones I, LAM T, Faragher I, Chan S
Background: Complete pathological response (pCR) to chemoradiation for rectal cancer improves local recurrence compared with those without pCR. Chemoradiation can potentially be tailored to those who are likely to receive the most benefit if we can pinpoint determinants of pCR. We aim to determine if there are clinical markers to predict response.
Methods: A retrospective analysis was performed on patients with rectal cancer diagnosed between 1st January 1998 and 31st December 2010 who underwent neo-adjuvant chemoradiation and surgery. Patient age, gender, stage at diagnosis, pre-operative CEA and time from cessation of chemoradiation to surgery were investigated. Univariate analysis and binary logistic regression was performed on each variable. Differences in 5 year local recurrence and overall survival were assessed using Kaplan Meier survival estimates.
Results: 300 patients were eligible for study and 57 patients (19%) had pCR. The variables associated with an increased rate of PCR was CEA level and completion of full planned dose of radiation. The 5-year local recurrence rate was 2.7%. There were 9 local recurrences during the study period. None of these were in the PCR group, but this did not reach significance.
Discussion: A pre-operative CEA below the normal limit (2.5ng/L) and completion of radiation appear to be statistically significant in determining the likelihood of having pCR following chemoradiation. This may be useful in decision making for patients who may not tolerate chemoradiation. Further research into molecular determinants of response identified at initial biopsy may be more useful in the clinical decision making for rectal cancers.
Presenting Author Biography
Tracy is a trainee in General Surgery at Western Health and have recently successfully completed her fellowship exams. As part of her Colorectal term she was involved in this study about rectal cancers and pathological complete response following neoadjuvant chemoradiotherapy. She is currently enjoying post-exam life.